ANCA-associated vasculitis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 30
• BCMA 14
• CD20 2
• AKT 0
• CTLA-4 0
• CD38 1
• IL-15 1
• IL-4 0
• mTOR 0
• PI3K 0
• SGLT2 1
• STAT3 0
• VEGF 0

4 of 4+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-CSA

  TwinDEEPS – Twinning deep-ocean exploration and observation capacity for sustainable development

  Centro Interdisciplinar de Investigacao Marinha e Ambiental· Matosinhos, Portugal· EU contribution €1,498,973· until Jun 2027· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Mucosal Breaks of Bacteria Trigger Pathogenic B-cell Responses in ANCA-associated Vasculitis (Breaking ANCA)

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €296,296· until Apr 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  EXPanding AAV gene therapy by EDITing (EXPEDITE)

  Fondazione Telethon Ets· Roma, Italy· EU contribution €2,492,303· until Oct 2028

• European Commission (Horizon Europe) · HORIZON-RIA

  Preclinical development of a 3rd-generation interleukin-2 targeted to inflammatory sites (TiilT)

  Sorbonne Universite· Paris, France· EU contribution €5,605,576· until May 2028· 6 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  Next-generation AAV vectors for liver-directed gene therapy (AAVolution)

  Fondazione Telethon Ets· Roma, Italy· EU contribution €4,500,000· until Sept 2027· 5 countries

5 of 5 running projects, newest first. Listed amounts together: €14.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

  NCT06508346· The Children's Hospital of Zhejiang University School of Medicine· Updated 16 Jun 2026

  “no participants enrolled”Registry text, quoted unchanged. Source

• Suspended

  Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases

  NCT06549296· Nanjing Bioheng Biotech Co., Ltd.· Updated 3 Feb 2026

  “R\&D strategy adjustment”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of RD06-04 in Patients With Active Autoimmune Diseases

  NCT06548620· Nanjing Bioheng Biotech Co., Ltd.· Updated 3 Feb 2026

  “R\&D strategy adjustment”Registry text, quoted unchanged. Source

• Terminated

  IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

  NCT06462144· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Updated 28 Jan 2026

  “The collaborating party has adjusted its R\&D strategy and terminated the study.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

  NCT07388277· Marcela V. Maus, M.D.,Ph.D.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 2
• Mendelian Randomization Analysis 1
• Gene Expression Profiling 8
• Proteomics 2
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 1
• Magnetic Resonance Imaging 14
• Machine Learning 3
• Cohort Studies 16
• Genome-Wide Association Study 3

• Pretreatment neutrophil-to-lymphocyte ratio is associated with clinical phenotypes and infection-related mortality in microscopic polyangiitis: the multicentre REVEAL cohort study.

  Front Immunol, Oct 2026

• Clinical features and prognosis of EGPA-associated peripheral neuropathy: a multicentre REVEAL cohort study.

  J Neurol, Oct 2026

• Cardiovascular and thromboembolic risk in ANCA-associated vasculitis: a nationwide matched cohort study by disease, sex and familial risk.

  Rheumatology (Oxford), Sept 2026

• Clinical and electrodiagnostic features of nerve conduction study-classified peripheral neuropathy in symptomatic patients with antineutrophil cytoplasmic antibody-associated vasculitis: a single-centre cohort study.

  Front Immunol, Jul 2026

• Differences in chest HRCT findings in relation to ANCA subtypes in ANCA-associated vasculitis.

  Respir Investig, May 2026

• Genetic burden across core genes of the PI3K-AKT-mTOR pathway is associated with susceptibility to microscopic polyangiitis: a Chinese cohort study.

  Front Immunol, Apr 2026

• Risk and trends of severe infection in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a two-part population-based trajectory analysis.

  Clin Rheumatol, Apr 2026

• Association Between Serum Syndecan-1 Levels and Relapse in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Medical Record-based Cohort Study in Japan.

  J Clin Rheumatol, Mar 2026

• Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort.

  Arthritis Rheumatol, Mar 2026

• Predictors of glucocorticoid-free clinical remission in patients with newly diagnosed microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study using a nationwide registry in Japan (J-CANVAS).

  Arthritis Res Ther, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.